MedTrace Logo

TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)

NCT00107887 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17415

Last updated 2011-06-15

No results posted yet for this study

Summary

The purpose of this study is to determine if implementing a policy of widespread INH (Isoniazid) prophylaxis therapy in HIV-infected patients with access to antiretroviral therapy reduces the incidence of active TB disease in the HIV clinic population.

Conditions

Interventions

DRUG

INH preventive therapy

Clinics will receive training regarding the use of IPT for prevention of Tuberculosis

DRUG

TST (tuberculin skin test)

Clinics will be trained in the use of TST for assessing exposure to TB

Sponsors & Collaborators

  • Consortium to Respond Effectively to the AIDS/Tuberculosis Epidemic

    collaborator OTHER

  • Communicable Disease Program, Brazil

    collaborator OTHER_GOV

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Valeria Saraceni, MD · City of Rio De Janeiro Municipal Health Secretariat

  • Richard E Chaisson, M.D. · Johns Hopkins University

  • Betina Durovni, M.D. · City of Rio de Janeiro Municipal Health Secretariat

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00107887 on ClinicalTrials.gov